Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 6;23(23):15440. doi: 10.3390/ijms232315440

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Overview of PROTAC degraders in clinical trials for cancer treatment. AR: androgen receptor; BCL-xL: B-cell lymphoma-extra large; BRAF: v-raf murine sarcoma viral oncogene homolog B1; BRD: bromodomain-containing protein; BTK: Bruton’s tyrosine kinase; DLBCL: diffuse large B cell lymphoma; EGFR: epidermal growth factor receptor; ER: estrogen receptor; IND: investigational new drug, LGL: large granular lymphocyte; mCRPC: metastatic castration-resistant prostate cancer; MDM2: mouse double minute 2; NSCLC: non-small cell lung cancer; NTRK: neurotrophic tyrosine receptor kinase; R/R: relapsed/refractory; SMARCB1: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily B, member 1; STAT3: signal transducer and activator of transcription 3.